Introduction: The interferon pathway plays a critical role in triggering the immune response to SARS-CoV-2, and these gene variants may be involved in the severity of COVID-19. This study aimed to analyze the frequency of three gene variants of OAS and RNASEL with the occurrence of COVID-19 symptoms and disease outcome. Methods: This cross-sectional study included 104 patients with SARS-CoV-2 infection, of which 34 were asymptomatic COVID-19, and 70 were symptomatic cases. The variants rs486907 (RNASEL), rs10774671 (OAS1), rs1293767 (OAS2), and rs2285932 (OAS3) were screened and discriminated using a predesigned 5′-nuclease assay with TaqMan probes. Results: Patients with the allele C of the OAS2 gene rs1293767 (OR = 0.36, 95% CI: 0.15–0.83, p = 0.014) and allele T of the OAS3 gene rs2285932 (OR = 0.39, 95% CI: 0.2–0.023, p = 0.023) have lower susceptibility to developing symptomatic COVID-19. The genotype frequencies (G/G, G/C, and C/C) of rs1293767 for that comparison were 64.7%, 29.4%, and 5.9% in the asymptomatic group and 95.2%, 4.8%, and 0% in severe disease (p < 0.05). Conclusions: Our data indicate that individuals carrying the C allele of the OAS2 gene rs1293767 and the T allele of the OAS3 gene rs2285932 are less likely to develop symptomatic COVID-19, suggesting these genetic variations may confer a protective effect among the Mexican study population. Furthermore, the observed differences in genotype frequencies between asymptomatic individuals and those with severe disease emphasize the potential of these variants as markers for disease severity. These insights enhance our understanding of the genetic factors that may influence the course of COVID-19 and underscore the potential for genetic screening in identifying individuals at increased risk for severe disease outcomes.

Introduction: The COVID-19 pandemic created an urgent need for safe and accessible outpatient treatments. Polymerized type I collagen (PTIC) has demonstrated potential immunomodulatory effects, but its clinical utility in patients with COVID-19 remains underexplored. This study aimed to evaluate the clinical evolution and health outcomes of a cohort of patients with COVID-19 treated with standard medical care plus PTIC during the pandemic emergency, in order to explore its potential role as an adjuvant therapy. Methods: A retrospective cohort study was conducted in 46 outpatients with confirmed COVID-19 treated with PTIC (Fibroquel^®) plus standard care, and 15 controls with standard care alone. Clinical and laboratory data were collected on Days 1 and 10. Patients were stratified by COVID-19 severity and SARS-CoV-2 variant. Analyses included odds ratios and Kaplan–Meier survival curves. Results: Oxygen saturation levels increased significantly from 88.5 ± 5.22 to 95.1 ± 2.07 after PTIC treatment. Supplemental oxygen was required for 26.1% of patients receiving treatment, compared to 60% of those in the untreated group (p < 0.05). Complete recovery was observed in all patients treated with PTIC, compared with 80% recovery in the standard care group. There were no deaths from COVID-19 in the PTIC group. In contrast, 20% of the participants in the untreated group died due to complications from the disease (p = 0.013). PTIC improved the survival rate of patients with the disease. Conclusions: PTIC significantly improved clinical parameters in patients with COVID-19. It improves oxygen saturation levels, decreases the need for supplemental oxygen, and improves survival compared to patients who are not treated with PTIC. Additional studies are needed to validate the use of PTIC as an adjunctive therapy for patients with COVID-19.